The FDA is reevaluating GlaxoSmithKline’s blood cancer drug Blenrep following mixed results from two phase 3 trials and mounting concerns about eye-related side effects and dosing. The agency is ...

With rising cell phone screen time, increasing temperature heat and worsening environmental pollution, protecting eye health is more ...

The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

A combination of routine eye scans and AI has created a powerful new way of measuring nearsightedness to better predict ...